Explanipedia

Steroid Sulfatase Regulates Metabolic Reprogramming in Advanced Prostate Cancer Open

Masuda Sharifi, Cameron M. Armstrong, Shu Ning, Amy R. Leslie, Zachary A. Schaaf , et al. · 2025

Background/Objective: The expression of human steroid sulfatase (STS) is upregulated in castration-resistant prostate cancer (CRPC) and is associated with resistance to anti-androgen drugs, such as enzalutamide (Enza) and abiraterone (Abi)…

Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

supplementary data

Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

supplementary data

Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

supplementary data

Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

supplementary data

Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

supplementary figure

Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

Supplementary data

Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

Supplementary data

Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

supplementary data

Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

supplementary data

Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2025

supplementary figure

Figure 4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

PINK1 expression is increased in 2B-OlapR cells and associated with negative patient prognosis. Treating 2B-OlapR cells with siPINK1 ASOs decreases PINK1 expression and protein level, as well as cell growth, and improves olaparib efficacy.…

Figure 3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

Mitochondrial live stain and ETC functional test demonstrate higher function in 2B-OlapR cells. A, Left, MitoTracker staining counterstained with nuclear-specific DAPI reveals higher amounts of relative mitochondrial mass in 2B-Olap…

Figure 2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

Seahorse Mito Stress Test assay results comparing C4-2B and 2B-OlapR cells at basal state and with mitochondrial inhibitor supplementation to deduce relative function. A and B, Mito Stress Test summary graphic representing di…

Figure S1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

supplementary figure

Figure S4 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

supplementary data

Figure 5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

Seahorse Mito Stress Test assay results comparing 2B-OlapR cells with and without siPINK treatment at basal state and with mitochondrially relevant pharmacologic supplementation to deduce relative function convey decreased function after P…

Figure 6 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

Inhibiting PINK1 expression decreases relative active mitochondria and lowers ETCC1 activity. A, Left, 2B-OlapR cells treated with siPINK1 show lower relative positive MitoTracker staining. 10× images shown, with 20× crops within. R…

Figure S3 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

supplementary data

Data from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

Olaparib, a PARP inhibitor, is a targeted therapy used in treating various cancers, including castration-resistant prostate cancer. Despite its efficacy, resistance to olaparib remains a significant challenge. Understanding the molecular m…

Figure S2 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

supplementary data

Figure S5 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

Supplementary data

Figure 1 from PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

Gene enrichment in olaparib-resistant derived C4-2B cells (2B-OlapR) related to OxPhos. A, Hallmark collection gene sets in 2B-OlapR cells, with the OxPhos gene set the most enriched. B–E, Gene set expression heatmap for full…

Data from LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy Open

Shu Ning, Cameron M. Armstrong, Enming Xing, Amy R. Leslie, Richard Y. Gao , et al. · 2024

The development of resistance to current standard-of-care treatments, such as androgen receptor (AR) targeting therapies, remains a major challenge in the management of advanced prostate cancer. There is an urgent need for new therapeutic …

Supplementary Information from LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy Open

Shu Ning, Cameron M. Armstrong, Enming Xing, Amy R. Leslie, Richard Y. Gao , et al. · 2024

Suppl. Figure 1-10, Table 1-2.

PINK1-Mediated Mitochondrial Activity Confers Olaparib Resistance in Prostate Cancer Cells Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Richard Y. Gao , et al. · 2024

Olaparib, a PARP inhibitor, is a targeted therapy used in treating various cancers, including castration-resistant prostate cancer. Despite its efficacy, resistance to olaparib remains a significant challenge. Understanding the molecular m…

LX1 Dual Targets AR Variants and AKR1C3 in Advanced Prostate Cancer Therapy Open

Shu Ning, Cameron M. Armstrong, Enming Xing, Amy R. Leslie, Richard Y. Gao , et al. · 2024

The development of resistance to current standard-of-care treatments, such as androgen receptor (AR) targeting therapies, remains a major challenge in the management of advanced prostate cancer. There is an urgent need for new therapeutic …

IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer Open

Amy R. Leslie, Shu Ning, Cameron M. Armstrong, Leandro S. D’Abronzo, Masuda Sharifi , et al. · 2024

Therapeutic Resistance Models and Treatment Sequencing in Advanced Prostate Cancer Open

Zachary A. Schaaf, Shu Ning, Amy R. Leslie, Masuda Sharifi, Xianrui Han , et al. · 2023

Current common treatments for castration-resistant prostate cancer (CRPC) typically belong to one of three major categories: next-generation anti-androgen therapies (NGAT) including enzalutamide, abiraterone acetate, apalutamide, and darol…

Supplementary Data from Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment Open

Shu Ning, Chengfei Liu, Wei Lou, Joy C. Yang, Alan P. Lombard , et al. · 2023

Supplementary Data from Bioengineered BERA-Wnt5a siRNA Targeting Wnt5a/FZD2 Signaling Suppresses Advanced Prostate Cancer Tumor Growth and Enhances Enzalutamide Treatment

Masuda Sharifi YOU? Author Swipe